Theravance Biopharma
TBPH
181 hedge funds and large institutions have $818M invested in Theravance Biopharma in 2026 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 64 increasing their positions, 55 reducing their positions, and 26 closing their positions.
38% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 26
16% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 55
4% more funds holding
Funds holding: 174 → 181 (+7)
0% more capital invested
Capital invested by funds: $814M → $818M (+$3.38M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
4.13% less ownership
Funds ownership: 97.42% → 93.29% (-4.1%)
92% less call options, than puts
Call options by funds: $243K | Put options by funds: $2.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$12.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.96M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$5M |
| 4 |
BlackRock
New York
|
+$4.41M |
| 5 |
D.E. Shaw & Co
New York
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
-$23.3M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.56M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$5.53M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$5.32M |
| 5 |
MAP
Madison Avenue Partners
New York
|
-$4.95M |
TBPH Hedge Fund Activity: Q2 2026 in Review
181 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2026, worth a combined $818M — up 0.42% from $814M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new TBPH positions and 26 closed out — a net gain of 10 holders — while 64 added to existing stakes and 55 trimmed.
The largest buyer was Mackenzie Financial, adding an estimated $12.2M. The largest seller was Newtyn Management, cutting an estimated $23.3M.
- 181 institutional investors held Theravance Biopharma (TBPH) as of Q2 2026, up from 174 in Q1 2026.
- Funds reported $818M of Theravance Biopharma stock for Q2 2026, up 0.42% quarter-over-quarter.
- 36 funds opened new Theravance Biopharma positions in Q2 2026 and 26 closed out, a net change of +10 holders.
- The largest Theravance Biopharma buyer in Q2 2026 was Mackenzie Financial, an estimated $12.2M added.
- The largest Theravance Biopharma seller in Q2 2026 was Newtyn Management, an estimated $23.3M sold.
Based on aggregated 13F filings for Q2 2026.